Infectious Disease Alert – February 1, 2018
February 1, 2018
View Issues
-
Adverse Reactions to Antibiotics in Patients Receiving Outpatient Parenteral Antimicrobial Therapy
Approximately one-fifth of outpatient parenteral antimicrobial therapy recipients developed a clinically significant antimicrobial-related adverse drug event.
-
Letermovir Prophylaxis Is Effective in Preventing Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation
A Phase III, randomized, double-blind, placebo-controlled superiority trial that included patients 18 years of age or older undergoing allogeneic hematopoietic stem cell transplantation found that prophylaxis with letermovir resulted in significantly lower risk for cytomegalovirus infection in the first 24 weeks than placebo. Safety and adverse events were similar between letermovir and placebo.
-
Pneumococcus, Sickle Cell Disease, Vaccination, and Penicillin
Even in the era of newborn screening, pneumococcal vaccination, and penicillin prophylaxis, children with sickle cell disease continue to be at risk of morbidity and mortality from invasive pneumococcal disease, mostly from non-vaccine serotypes.
-
Updated Recommendations for Prevention of Hepatitis B Virus Infection
New recommendations for prevention of hepatitis B virus infection focus on testing and management of newborns.
-
REPROVE: Ceftazidime-avibactam vs. Meropenem in Hospital-acquired Pneumonia
Ceftazidime-avibactam therapy was non-inferior to meropenem treatment in a double-blind, randomized trial that included patients with nosocomial pneumonia, including those with ventilator-associated pneumonia.
-
Root Causes of Hepatitis A Outbreak in California
During 2017, a large outbreak of hepatitis A was identified in California. The majority of patients were homeless. Addressing the problem of homelessness should be a priority for our country.
-
Infectious Disease Alert Updates
Providers Facilitate Transmission of Resistant Organisms; The Time Is Now — Stop CRKP